222 related articles for article (PubMed ID: 20050930)
1. Maintenance of treatment logs by haemophilia patients.
du Treil S; Rice J; Leissinger CA
Haemophilia; 2010 May; 16(3):545-7. PubMed ID: 20050930
[No Abstract] [Full Text] [Related]
2. Efficacy and safety evaluation of sucrose-formulated recombinant factor VIII for Taiwanese patients with haemophilia A.
Young JH; Liu HC; Hsueh EJ; Huang ML; Peng CT; Chen RL; Maas-Enriquez M; Achilles K
Haemophilia; 2009 Jul; 15(4):968-70. PubMed ID: 19473407
[No Abstract] [Full Text] [Related]
3. Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens.
Berntorp E
Haemophilia; 2009 Nov; 15(6):1219-27. PubMed ID: 19659939
[TBL] [Abstract][Full Text] [Related]
4. [Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIII or IX].
Iizuka A; Kuwashima M; Nagao T
Nihon Ketsueki Gakkai Zasshi; 1982 Sep; 45(5):987-92. PubMed ID: 6818811
[No Abstract] [Full Text] [Related]
5. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.
Shirahata A; Fukutake K; Higasa S; Mimaya J; Oka T; Shima M; Takamatsu J; Taki M; Taneichi M; Yoshioka A;
Haemophilia; 2011 Sep; 17(5):771-6. PubMed ID: 21682824
[TBL] [Abstract][Full Text] [Related]
6. [Inhibitor development after changing FVIII/IX products in patients with haemophilia].
Kocher S; Asmelash G; Makki V; Müller S; Krekeler S; Alesci S; Miesbach W
Hamostaseologie; 2012; 32 Suppl 1():S39-42. PubMed ID: 22961330
[TBL] [Abstract][Full Text] [Related]
7. Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors.
Ullman M; Hoots WK
Haemophilia; 2006 Dec; 12 Suppl 6():74-9; discussion 79-80. PubMed ID: 17123398
[TBL] [Abstract][Full Text] [Related]
8. Attitudes and practices with regard to circumcision in haemophilia patients in Southern Iran.
Haghpanah S; Ardeshiri R; Zahedi Z; Golzadeh MH; Silavizadeh S; Karimi M
Haemophilia; 2013 May; 19(3):e177-8. PubMed ID: 23490218
[No Abstract] [Full Text] [Related]
9. Adherence to prophylactic infusions of factor VIII or factor IX for haemophilia.
Thornburg CD; Pipe SW
Haemophilia; 2006 Mar; 12(2):198-9. PubMed ID: 16476098
[No Abstract] [Full Text] [Related]
10. Prophylaxis in haemophilia should be life-long.
Makris M
Blood Transfus; 2012 Apr; 10(2):165-8. PubMed ID: 22337280
[No Abstract] [Full Text] [Related]
11. A comparison of the treatment of patients with factor IX deficiency to that of those with factor VIII deficiency: results of an International Survey conducted as part of the International FIX Treatment Network.
Berntorp E; Shapiro AD; Waters J; Astermark J
Haemophilia; 2014 Sep; 20(5):e362-4. PubMed ID: 25156443
[No Abstract] [Full Text] [Related]
12. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
Björkman S; Folkesson A; Berntorp E
Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
[TBL] [Abstract][Full Text] [Related]
13. Current issues in prophylactic therapy for persons with hemophilia.
Dunn AL; Abshire TC
Acta Haematol; 2006; 115(3-4):162-71. PubMed ID: 16549891
[TBL] [Abstract][Full Text] [Related]
14. Treatment of hemophilia complicated by inhibitors.
Scand J Haematol Suppl; 1980; 35():135-64. PubMed ID: 6770458
[No Abstract] [Full Text] [Related]
15. Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States.
Thornburg CD; Carpenter S; Zappa S; Munn J; Leissinger C
Haemophilia; 2012 Jul; 18(4):568-74. PubMed ID: 22335526
[TBL] [Abstract][Full Text] [Related]
16. Choice of factor VIII/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15-25).
Meunier S; d'oiron R; Chambost H; Dolimier E; Guillet B;
Thromb Res; 2017 Mar; 151():17-22. PubMed ID: 28088606
[TBL] [Abstract][Full Text] [Related]
17. Identifying and overcoming barriers to prophylaxis in the management of haemophilia.
Petrini P
Haemophilia; 2007 Sep; 13 Suppl 2():16-22. PubMed ID: 17685919
[TBL] [Abstract][Full Text] [Related]
18. The natural history of mild haemophilia: a 30-year single centre experience.
Tagliaferri A; Di Perna C; Riccardi F; Pattacini C; Rivolta GF; Franchini M
Haemophilia; 2012 Mar; 18(2):166-74. PubMed ID: 21771207
[TBL] [Abstract][Full Text] [Related]
19. Development and psychometric evaluation of a novel tool for assessing patient perception and preference for haemophilia treatment (HaemoPREF).
Teal S; Brohan E; Hettema Y; Humphrey L; Willgoss T; Hudgens S; Westfeld M; Cappelleri JC
Haemophilia; 2014 Sep; 20(5):666-73. PubMed ID: 24720617
[TBL] [Abstract][Full Text] [Related]
20. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A.
Richards M; Williams M; Chalmers E; Liesner R; Collins P; Vidler V; Hanley J;
Br J Haematol; 2010 May; 149(4):498-507. PubMed ID: 20230411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
